Quantitative Systematic Strategies LLC Incyte Corp Transaction History

Quantitative Systematic Strategies LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 06, 2021	BUY	$76.02 - $100.5 $278,233 - $367,830	3,660 New	3,660 $297,000
Q1 2020 May 06, 2020	SELL	$63.18 - $85.97 $722,842 - $983,582	-11,441 Closed	0 $0
Q4 2019 Feb 11, 2020	BUY	$73.04 - $95.72 $311,807 - $408,628	4,269 Added 59.52%	11,441 $999,000
Q3 2019 Nov 07, 2019	SELL	$72.82 - $86.52 $516,075 - $613,167	-7,087 Reduced 49.7%	7,172 $532,000
Q2 2019 Jul 25, 2019	BUY	$73.52 - $88.7 $851,949 - $1.03 Million	11,588 Added 433.85%	14,259 $1.21 Million
Q1 2019 Apr 15, 2019	SELL	$63.56 - $88.17 $674,117 - $935,131	-10,606 Reduced 79.88%	2,671 $230,000
Q4 2018 Feb 12, 2019	BUY	$58.5 - $69.94 $236,866 - $283,187	4,049 Added 43.88%	13,277 $844,000
Q3 2018 Nov 14, 2018	BUY	$61.75 - $74.23 $569,829 - $684,994	9,228 New	9,228 $637,000
Q1 2018 May 04, 2018	SELL	$83.06 - $100.98 $265,293 - $322,530	-3,194 Closed	0 $0
Q4 2017 Feb 01, 2018	BUY	$93.56 - $116.6 $298,830 - $372,420	3,194	3,194 $303,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.8B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Quantitative Systematic Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on Quantitative Systematic Strategies LLC with notifications on news.